Global Irinotecan Market
Global Irinotecan Market

Irinotecan Comprehensive Study by Type (Irinotecan Hydrochloride Injection 40mg, Irinotecan Hydrochloride Injection 100mg, Other), Application (Colon cancer, Rectal cancer), Route of Administration (Oral, Injection) Players and Region - Global Market Outlook to 2026

Irinotecan Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Jun 2021 Edition 232 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
The study covers a detailed analysis segmented by key business segments i.e. by type (Irinotecan Hydrochloride Injection 40mg, Irinotecan Hydrochloride Injection 100mg and Other) , by application (Colon cancer and Rectal cancer) and major geographies. Research Analyst at AMA predicts that Asia Pacific Players will contribute to the maximum growth of Global Irinotecan market throughout the predicted period.

What is Irinotecan?
Irinotecan medication is given by injection into a vein by a health care professional. The dosage relies on your medical condition, body size, and response to treatment. If this medication comes into contact along with your skin, wash the skin immediately and completely with soap and water. If this medication gets into your eyes, mouth, or nose, flush completely with much waters. Indicated as first-line therapy (with 5-fluorouracil and leucovorin) for metastatic colorectal cancer (CRC); it's also indicated for CRC that has recurred or progressed following initial fluorouracil-based therapy. Irinotecan can cause both early and late-onset diarrhea. Both kinds of diarrhea could also be severe and appear to be mediated by different mechanisms. It is usually transient and only infrequently severe. Early-onset diarrhea is assumed to be a part of a cholinergic syndrome mediated by increased anticholinesterase activity of the irinotecan parent compound.

The competition is expected to become even more intense in the years to come due to entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Irinotecan market analysis report suggests strategies Players can follow and recommends key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, including:
  • West-Ward Pharmaceuticals (United States)
  • Pfizer (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Actiza Pharmaceutical (India)
  • Taj Pharma (India)
  • Cipla (India)
  • Salius (India)
  • Tecoland Corporation (United States)
  • ScinoPharm Taiwan, Ltd (Taiwan)
  • YAKULT HONSHA CO LTD (Japan)
  • Jiwan Pharmaceutical Technology (China)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.

Market Trend
Increased Awareness about Cancer Treatments among People and Increased Government Initiatives for Cancer Awareness
Restraints
  • Side Effects of the Colorectal Cancer Drugs
  • Stringent Government Rules and Regulations

Opportunities
Growth in the Healthcare Industry Worldwide and Increasing Number of Online Pharmacies

Key highlights of the Global Irinotecan market Study:
• CAGR of the market during the forecast period 2020-2026
• In-depth information on growth factors that will accelerate the Irinotecan market in next few years.
• Detailed Insights on futuristic trends and changing consumer behaviour
• Forecast of the Global Irinotecan market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Irinotecan Players

Transformation and Important Trigegrs:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Irinotecan market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Irinotecan market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Pharmaceutical Company, Distributors, Research Professionals and End-Users.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Frequently Asked Questions (FAQ):

1. Where the Irinotecan industry is heading?
Irinotecan Market is heading robustly to achieve new growth cycle.

2. Is Irinotecan market is changing from growth to value?
The Concentration Rate of Global Irinotecan market is dominated by Asia Pacific Players to generate healthy valuation by 2026.

3. Who are the key players profiled in the Irinotecan Market?
Companies that are profiled in Global Irinotecan Market are West-Ward Pharmaceuticals (United States), Pfizer (United States), Teva Pharmaceutical Industries Ltd. (Israel), Actiza Pharmaceutical (India), Taj Pharma (India), Cipla (India), Salius (India), Tecoland Corporation (United States), ScinoPharm Taiwan, Ltd (Taiwan), YAKULT HONSHA CO LTD (Japan) and Jiwan Pharmaceutical Technology (China) etc.
Report Objectives / Segmentation Covered
By Type
  • Irinotecan Hydrochloride Injection 40mg
  • Irinotecan Hydrochloride Injection 100mg
  • Other
By Application
  • Colon cancer
  • Rectal cancer
By Route of Administration
  • Oral
  • Injection

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Colorectal Cancer among People Worldwide
      • 3.2.2. Rise in the Number of Diagnostic Centres and Hospitals
    • 3.3. Market Trends
      • 3.3.1. Increased Awareness about Cancer Treatments among People
      • 3.3.2. Increased Government Initiatives for Cancer Awareness
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Irinotecan, by Type, Application, Route of Administration and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Irinotecan (Value)
      • 5.2.1. Global Irinotecan by: Type (Value)
        • 5.2.1.1. Irinotecan Hydrochloride Injection 40mg
        • 5.2.1.2. Irinotecan Hydrochloride Injection 100mg
        • 5.2.1.3. Other
      • 5.2.2. Global Irinotecan by: Application (Value)
        • 5.2.2.1. Colon cancer
        • 5.2.2.2. Rectal cancer
      • 5.2.3. Global Irinotecan by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injection
      • 5.2.4. Global Irinotecan Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Irinotecan: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. West-Ward Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Pfizer (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Actiza Pharmaceutical (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Taj Pharma (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cipla (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Salius (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Tecoland Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. ScinoPharm Taiwan, Ltd (Taiwan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. YAKULT HONSHA CO LTD (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Jiwan Pharmaceutical Technology (China)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Irinotecan Sale, by Type, Application, Route of Administration and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Irinotecan (Value)
      • 7.2.1. Global Irinotecan by: Type (Value)
        • 7.2.1.1. Irinotecan Hydrochloride Injection 40mg
        • 7.2.1.2. Irinotecan Hydrochloride Injection 100mg
        • 7.2.1.3. Other
      • 7.2.2. Global Irinotecan by: Application (Value)
        • 7.2.2.1. Colon cancer
        • 7.2.2.2. Rectal cancer
      • 7.2.3. Global Irinotecan by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injection
      • 7.2.4. Global Irinotecan Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Irinotecan: by Type(USD Million)
  • Table 2. Irinotecan Irinotecan Hydrochloride Injection 40mg , by Region USD Million (2015-2020)
  • Table 3. Irinotecan Irinotecan Hydrochloride Injection 100mg , by Region USD Million (2015-2020)
  • Table 4. Irinotecan Other , by Region USD Million (2015-2020)
  • Table 5. Irinotecan: by Application(USD Million)
  • Table 6. Irinotecan Colon cancer , by Region USD Million (2015-2020)
  • Table 7. Irinotecan Rectal cancer , by Region USD Million (2015-2020)
  • Table 8. Irinotecan: by Route of Administration(USD Million)
  • Table 9. Irinotecan Oral , by Region USD Million (2015-2020)
  • Table 10. Irinotecan Injection , by Region USD Million (2015-2020)
  • Table 11. South America Irinotecan, by Country USD Million (2015-2020)
  • Table 12. South America Irinotecan, by Type USD Million (2015-2020)
  • Table 13. South America Irinotecan, by Application USD Million (2015-2020)
  • Table 14. South America Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 15. Brazil Irinotecan, by Type USD Million (2015-2020)
  • Table 16. Brazil Irinotecan, by Application USD Million (2015-2020)
  • Table 17. Brazil Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 18. Argentina Irinotecan, by Type USD Million (2015-2020)
  • Table 19. Argentina Irinotecan, by Application USD Million (2015-2020)
  • Table 20. Argentina Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 21. Rest of South America Irinotecan, by Type USD Million (2015-2020)
  • Table 22. Rest of South America Irinotecan, by Application USD Million (2015-2020)
  • Table 23. Rest of South America Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 24. Asia Pacific Irinotecan, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Irinotecan, by Type USD Million (2015-2020)
  • Table 26. Asia Pacific Irinotecan, by Application USD Million (2015-2020)
  • Table 27. Asia Pacific Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 28. China Irinotecan, by Type USD Million (2015-2020)
  • Table 29. China Irinotecan, by Application USD Million (2015-2020)
  • Table 30. China Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 31. Japan Irinotecan, by Type USD Million (2015-2020)
  • Table 32. Japan Irinotecan, by Application USD Million (2015-2020)
  • Table 33. Japan Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 34. India Irinotecan, by Type USD Million (2015-2020)
  • Table 35. India Irinotecan, by Application USD Million (2015-2020)
  • Table 36. India Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 37. South Korea Irinotecan, by Type USD Million (2015-2020)
  • Table 38. South Korea Irinotecan, by Application USD Million (2015-2020)
  • Table 39. South Korea Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 40. Taiwan Irinotecan, by Type USD Million (2015-2020)
  • Table 41. Taiwan Irinotecan, by Application USD Million (2015-2020)
  • Table 42. Taiwan Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 43. Australia Irinotecan, by Type USD Million (2015-2020)
  • Table 44. Australia Irinotecan, by Application USD Million (2015-2020)
  • Table 45. Australia Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Irinotecan, by Type USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Irinotecan, by Application USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 49. Europe Irinotecan, by Country USD Million (2015-2020)
  • Table 50. Europe Irinotecan, by Type USD Million (2015-2020)
  • Table 51. Europe Irinotecan, by Application USD Million (2015-2020)
  • Table 52. Europe Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 53. Germany Irinotecan, by Type USD Million (2015-2020)
  • Table 54. Germany Irinotecan, by Application USD Million (2015-2020)
  • Table 55. Germany Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 56. France Irinotecan, by Type USD Million (2015-2020)
  • Table 57. France Irinotecan, by Application USD Million (2015-2020)
  • Table 58. France Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 59. Italy Irinotecan, by Type USD Million (2015-2020)
  • Table 60. Italy Irinotecan, by Application USD Million (2015-2020)
  • Table 61. Italy Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 62. United Kingdom Irinotecan, by Type USD Million (2015-2020)
  • Table 63. United Kingdom Irinotecan, by Application USD Million (2015-2020)
  • Table 64. United Kingdom Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 65. Netherlands Irinotecan, by Type USD Million (2015-2020)
  • Table 66. Netherlands Irinotecan, by Application USD Million (2015-2020)
  • Table 67. Netherlands Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 68. Rest of Europe Irinotecan, by Type USD Million (2015-2020)
  • Table 69. Rest of Europe Irinotecan, by Application USD Million (2015-2020)
  • Table 70. Rest of Europe Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 71. MEA Irinotecan, by Country USD Million (2015-2020)
  • Table 72. MEA Irinotecan, by Type USD Million (2015-2020)
  • Table 73. MEA Irinotecan, by Application USD Million (2015-2020)
  • Table 74. MEA Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 75. Middle East Irinotecan, by Type USD Million (2015-2020)
  • Table 76. Middle East Irinotecan, by Application USD Million (2015-2020)
  • Table 77. Middle East Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 78. Africa Irinotecan, by Type USD Million (2015-2020)
  • Table 79. Africa Irinotecan, by Application USD Million (2015-2020)
  • Table 80. Africa Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 81. North America Irinotecan, by Country USD Million (2015-2020)
  • Table 82. North America Irinotecan, by Type USD Million (2015-2020)
  • Table 83. North America Irinotecan, by Application USD Million (2015-2020)
  • Table 84. North America Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 85. United States Irinotecan, by Type USD Million (2015-2020)
  • Table 86. United States Irinotecan, by Application USD Million (2015-2020)
  • Table 87. United States Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 88. Canada Irinotecan, by Type USD Million (2015-2020)
  • Table 89. Canada Irinotecan, by Application USD Million (2015-2020)
  • Table 90. Canada Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 91. Mexico Irinotecan, by Type USD Million (2015-2020)
  • Table 92. Mexico Irinotecan, by Application USD Million (2015-2020)
  • Table 93. Mexico Irinotecan, by Route of Administration USD Million (2015-2020)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Irinotecan: by Type(USD Million)
  • Table 106. Irinotecan Irinotecan Hydrochloride Injection 40mg , by Region USD Million (2021-2026)
  • Table 107. Irinotecan Irinotecan Hydrochloride Injection 100mg , by Region USD Million (2021-2026)
  • Table 108. Irinotecan Other , by Region USD Million (2021-2026)
  • Table 109. Irinotecan: by Application(USD Million)
  • Table 110. Irinotecan Colon cancer , by Region USD Million (2021-2026)
  • Table 111. Irinotecan Rectal cancer , by Region USD Million (2021-2026)
  • Table 112. Irinotecan: by Route of Administration(USD Million)
  • Table 113. Irinotecan Oral , by Region USD Million (2021-2026)
  • Table 114. Irinotecan Injection , by Region USD Million (2021-2026)
  • Table 115. South America Irinotecan, by Country USD Million (2021-2026)
  • Table 116. South America Irinotecan, by Type USD Million (2021-2026)
  • Table 117. South America Irinotecan, by Application USD Million (2021-2026)
  • Table 118. South America Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 119. Brazil Irinotecan, by Type USD Million (2021-2026)
  • Table 120. Brazil Irinotecan, by Application USD Million (2021-2026)
  • Table 121. Brazil Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 122. Argentina Irinotecan, by Type USD Million (2021-2026)
  • Table 123. Argentina Irinotecan, by Application USD Million (2021-2026)
  • Table 124. Argentina Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 125. Rest of South America Irinotecan, by Type USD Million (2021-2026)
  • Table 126. Rest of South America Irinotecan, by Application USD Million (2021-2026)
  • Table 127. Rest of South America Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 128. Asia Pacific Irinotecan, by Country USD Million (2021-2026)
  • Table 129. Asia Pacific Irinotecan, by Type USD Million (2021-2026)
  • Table 130. Asia Pacific Irinotecan, by Application USD Million (2021-2026)
  • Table 131. Asia Pacific Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 132. China Irinotecan, by Type USD Million (2021-2026)
  • Table 133. China Irinotecan, by Application USD Million (2021-2026)
  • Table 134. China Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 135. Japan Irinotecan, by Type USD Million (2021-2026)
  • Table 136. Japan Irinotecan, by Application USD Million (2021-2026)
  • Table 137. Japan Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 138. India Irinotecan, by Type USD Million (2021-2026)
  • Table 139. India Irinotecan, by Application USD Million (2021-2026)
  • Table 140. India Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 141. South Korea Irinotecan, by Type USD Million (2021-2026)
  • Table 142. South Korea Irinotecan, by Application USD Million (2021-2026)
  • Table 143. South Korea Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 144. Taiwan Irinotecan, by Type USD Million (2021-2026)
  • Table 145. Taiwan Irinotecan, by Application USD Million (2021-2026)
  • Table 146. Taiwan Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 147. Australia Irinotecan, by Type USD Million (2021-2026)
  • Table 148. Australia Irinotecan, by Application USD Million (2021-2026)
  • Table 149. Australia Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Irinotecan, by Type USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Irinotecan, by Application USD Million (2021-2026)
  • Table 152. Rest of Asia-Pacific Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 153. Europe Irinotecan, by Country USD Million (2021-2026)
  • Table 154. Europe Irinotecan, by Type USD Million (2021-2026)
  • Table 155. Europe Irinotecan, by Application USD Million (2021-2026)
  • Table 156. Europe Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 157. Germany Irinotecan, by Type USD Million (2021-2026)
  • Table 158. Germany Irinotecan, by Application USD Million (2021-2026)
  • Table 159. Germany Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 160. France Irinotecan, by Type USD Million (2021-2026)
  • Table 161. France Irinotecan, by Application USD Million (2021-2026)
  • Table 162. France Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 163. Italy Irinotecan, by Type USD Million (2021-2026)
  • Table 164. Italy Irinotecan, by Application USD Million (2021-2026)
  • Table 165. Italy Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 166. United Kingdom Irinotecan, by Type USD Million (2021-2026)
  • Table 167. United Kingdom Irinotecan, by Application USD Million (2021-2026)
  • Table 168. United Kingdom Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 169. Netherlands Irinotecan, by Type USD Million (2021-2026)
  • Table 170. Netherlands Irinotecan, by Application USD Million (2021-2026)
  • Table 171. Netherlands Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 172. Rest of Europe Irinotecan, by Type USD Million (2021-2026)
  • Table 173. Rest of Europe Irinotecan, by Application USD Million (2021-2026)
  • Table 174. Rest of Europe Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 175. MEA Irinotecan, by Country USD Million (2021-2026)
  • Table 176. MEA Irinotecan, by Type USD Million (2021-2026)
  • Table 177. MEA Irinotecan, by Application USD Million (2021-2026)
  • Table 178. MEA Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 179. Middle East Irinotecan, by Type USD Million (2021-2026)
  • Table 180. Middle East Irinotecan, by Application USD Million (2021-2026)
  • Table 181. Middle East Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 182. Africa Irinotecan, by Type USD Million (2021-2026)
  • Table 183. Africa Irinotecan, by Application USD Million (2021-2026)
  • Table 184. Africa Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 185. North America Irinotecan, by Country USD Million (2021-2026)
  • Table 186. North America Irinotecan, by Type USD Million (2021-2026)
  • Table 187. North America Irinotecan, by Application USD Million (2021-2026)
  • Table 188. North America Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 189. United States Irinotecan, by Type USD Million (2021-2026)
  • Table 190. United States Irinotecan, by Application USD Million (2021-2026)
  • Table 191. United States Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 192. Canada Irinotecan, by Type USD Million (2021-2026)
  • Table 193. Canada Irinotecan, by Application USD Million (2021-2026)
  • Table 194. Canada Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 195. Mexico Irinotecan, by Type USD Million (2021-2026)
  • Table 196. Mexico Irinotecan, by Application USD Million (2021-2026)
  • Table 197. Mexico Irinotecan, by Route of Administration USD Million (2021-2026)
  • Table 198. Research Programs/Design for This Report
  • Table 199. Key Data Information from Secondary Sources
  • Table 200. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Irinotecan: by Type USD Million (2015-2020)
  • Figure 5. Global Irinotecan: by Application USD Million (2015-2020)
  • Figure 6. Global Irinotecan: by Route of Administration USD Million (2015-2020)
  • Figure 7. South America Irinotecan Share (%), by Country
  • Figure 8. Asia Pacific Irinotecan Share (%), by Country
  • Figure 9. Europe Irinotecan Share (%), by Country
  • Figure 10. MEA Irinotecan Share (%), by Country
  • Figure 11. North America Irinotecan Share (%), by Country
  • Figure 12. Global Irinotecan share by Players 2020 (%)
  • Figure 13. Global Irinotecan share by Players (Top 3) 2020(%)
  • Figure 14. Global Irinotecan share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. West-Ward Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 17. West-Ward Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 18. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 19. Pfizer (United States) Revenue: by Geography 2020
  • Figure 20. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 21. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 22. Actiza Pharmaceutical (India) Revenue, Net Income and Gross profit
  • Figure 23. Actiza Pharmaceutical (India) Revenue: by Geography 2020
  • Figure 24. Taj Pharma (India) Revenue, Net Income and Gross profit
  • Figure 25. Taj Pharma (India) Revenue: by Geography 2020
  • Figure 26. Cipla (India) Revenue, Net Income and Gross profit
  • Figure 27. Cipla (India) Revenue: by Geography 2020
  • Figure 28. Salius (India) Revenue, Net Income and Gross profit
  • Figure 29. Salius (India) Revenue: by Geography 2020
  • Figure 30. Tecoland Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 31. Tecoland Corporation (United States) Revenue: by Geography 2020
  • Figure 32. ScinoPharm Taiwan, Ltd (Taiwan) Revenue, Net Income and Gross profit
  • Figure 33. ScinoPharm Taiwan, Ltd (Taiwan) Revenue: by Geography 2020
  • Figure 34. YAKULT HONSHA CO LTD (Japan) Revenue, Net Income and Gross profit
  • Figure 35. YAKULT HONSHA CO LTD (Japan) Revenue: by Geography 2020
  • Figure 36. Jiwan Pharmaceutical Technology (China) Revenue, Net Income and Gross profit
  • Figure 37. Jiwan Pharmaceutical Technology (China) Revenue: by Geography 2020
  • Figure 38. Global Irinotecan: by Type USD Million (2021-2026)
  • Figure 39. Global Irinotecan: by Application USD Million (2021-2026)
  • Figure 40. Global Irinotecan: by Route of Administration USD Million (2021-2026)
  • Figure 41. South America Irinotecan Share (%), by Country
  • Figure 42. Asia Pacific Irinotecan Share (%), by Country
  • Figure 43. Europe Irinotecan Share (%), by Country
  • Figure 44. MEA Irinotecan Share (%), by Country
  • Figure 45. North America Irinotecan Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • West-Ward Pharmaceuticals (United States)
  • Pfizer (United States)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Actiza Pharmaceutical (India)
  • Taj Pharma (India)
  • Cipla (India)
  • Salius (India)
  • Tecoland Corporation (United States)
  • ScinoPharm Taiwan, Ltd (Taiwan)
  • YAKULT HONSHA CO LTD (Japan)
  • Jiwan Pharmaceutical Technology (China)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation